SEC Form EFFECT filed by Akebia Therapeutics Inc.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | September 12, 2024 4:30 P.M. |
Form: | S-3 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | September 12, 2024 4:30 P.M. |
Form: | S-3 | ||||||
|
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/29/2023 | $4.00 | Buy | BTIG Research |
8/28/2023 | $3.75 | Neutral → Buy | H.C. Wainwright |
5/31/2023 | $2.00 → $4.00 | Neutral → Overweight | Piper Sandler |
3/31/2022 | $10.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
3/31/2022 | Buy → Hold | Needham | |
3/31/2022 | $6.00 → $2.00 | Buy → Neutral | Mizuho |
3/31/2022 | $6.00 → $2.00 | Overweight → Neutral | Piper Sandler |
11/11/2021 | $6.00 → $10.00 | Buy | HC Wainwright & Co. |
Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of careTrial aims to build a body of real-world evidence to understand the potential benefits of treating patients with VafseoCAMBRIDGE, Mass., Sept. 5, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's largest privately held and fastest-growing kidney care provider, today announced plans to begin a collaborative clinical trial of recently approved Vafseo. The first patient in this trial is expected to be enrolled this ye
CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia's common stock on August 30, 2024. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney d
CAMBRIDGE, Mass., Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)"
BTIG Research resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $4.00
H.C. Wainwright upgraded Akebia Therapeutics from Neutral to Buy and set a new price target of $3.75
Piper Sandler upgraded Akebia Therapeutics from Neutral to Overweight and set a new price target of $4.00 from $2.00 previously
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
3 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
EFFECT - Akebia Therapeutics, Inc. (0001517022) (Filer)
S-3 - Akebia Therapeutics, Inc. (0001517022) (Filer)
10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)
Vafseo® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 millionAkebia to host conference call at 8:00 a.m. ET on August 8 CAMBRIDGE, Mass., Aug. 8, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2024, and recent business highlights. During the quarter, Akebia made significant progress across multiple initiatives related to the commerci
Akebia to Host Conference Call on August 8, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, prior to the open of financial markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therap
Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economicsAnnounced Vafseo WAC pricing of $1,278 for a 30-day supplySubmitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025Akebia to host investor conference call at 8:00 a.m. ET on July 11, 2024 CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced key updates pertaining to the commercial launch of Vafs
Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit percentage on annual net sales above $450 million. Akebia has the opportunity to buy down the royalty agreement beginning on July 1, 2027 with a one-time payment to CSL Vifor, which would decrease the royalty payments to a mid-single digit percentage of Akebia's annual net sales of Vafseo up to $450 million and eliminate the royalty payment on annual net sales above $450 million. Announced Vafseo WAC pricing of $1,278 for a 30-day supply Submitted TDAPA application for Vafseo in June 2024 and
Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity
CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut
CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)